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The interaction of a polyoxometal (POM), K6SiW11Co(H2O)O39.10H2O (K6) as a Keggin, with human serum
albumin (HSA) was studied by different methods and techniques. Binding studies show two sets of binding
sites for interaction of POM to HSA. Binding analysis and isothermal calorimetery revealed that, the first set
of binding site has lower number of bound ligand per mole of protein (Q), lower Hill constant (n), higher
binding constant (K), more negative entropy ('S) and more electrostatic interaction in comparison to the second
set of binding site. In addition, differential scanning calorimetery (DSC) and spectrophotometery data showed
that, there are two energetic domains. The first domain is less stable (lower Tm and Cp) which corresponds to
the tail segment of HSA and another with more stability is related to the head segment of HSA. Polyoxometal
also decreases the stability of protein as Tm, secondary and tertiary structure as well as quenching of the
fluorescence decrease. On other hand, perturbations in tertiary structure are more than secondary structure.
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Introduction
Albumin is a major plasma protein and binds to the
number of drugs altering their pharmacokinetics. It is single
chain polypeptide of 585 residues, which comprises about
60% of the plasma protein. It is the major contributor to the
oncotic of blood.1 In addition, it has been reported that
albumin is chiefly responsible for maintainance of blood
pH.2,3 The human serum albumin (HSA) is named a multi-
functional plasma carrier protein because of its ability to
bind to an unusually broad spectrum of ligands. These
includes inorganic cations, organic anions, various drugs,
amino acids, and perhaps most important and physiologi-
cally available hydrophobic molecules such as bilirubin and
fatty acids.1,4,5
In mammals, albumin is synthesized by the liver and
possesses a half-life in circulation of 19 days.6,7 Serum
albumin has been one of the most studied proteins for 40
years, because its primary structure is very well known for a
long time and its tertiary structure was determined a few
years ago by X-ray crystallography.5,6 Its primary structure is
characterized by low content of tryptophan, a high content of
cystein stabilizing a series of main loops, and charged amino
acids such as aspartic and glutamic acids, lysine and argi-
nine.5 The apparent repeating structural features, large and
small loops and connecting segments, suggest that albumin
evolved through a series of gene duplications.5 Its secondary
structure is constituted of 67% of helix of six turns and 17
disulfide bridge.5,8 The tertiary structure is composed by
three domains I, II, III. Each domain is constituted by a
cylinder formed by six helices, and each one of these
domains are constituted by two subdomains formed by three
helices that covalently linked by their double Cys bridge.
These subdomains are IAB, IC, IIAB, IIC, IIIAB, IIIC.5,9
The binding cavity in the domain IIIA is known to be able to
bind many ligands like, for example, digitoxin, ibuprofen
and tryptophan. Aspirin and iodinated aspirin derivatives
show nearly equal distributions between the binding sites
located in subdomains IIA and IIIA. Warfarin occupies a
single site in IIA.6,8 Many small aromatic carboxylic acids
are equally distributed in both IIA and IIIA.6 Since domains
II and III share a common interface. It is known that binding
to domain III leads to conformational changes affecting the
binding affinities to domain II. Trp214 residue plays an
important structural role in the formation of the IIA binding
site by limiting the solvent accessibility and besides that it
participates in additional hydrophobic packing interactions
at IIA-IIIA interface.7 Cys 34 used as a fluorescent probe to
monitor the surroundings of this residue.10-12
On the other hand, same as all of ligands, several com-
pounds such as polysulfates, polysulfunates, polycarbox-
ylates, polyphosphates and polyoxometalates (POM) have
been identified that pharmaceutical effect and inhibit an
early stage in the replicative cycle of the human immuno-
deficiency virus (HIV).13 Polyoxometalates are early transition
metal oxygen anion clusters. More specifically, they are
oligomeric aggregates of metal cations (usually the do
species VV, NbV, TaV, MoVI, and WVI bridged by oxide anions
that are formed by self-assembly processes. There are two
generic families of POMs, the isopoly and the heteropoly
